think it’s being overlooked that monepatel is a potential solution to a range of neurodegenrative disorders not just MND. Pathway for Alzheimers is impacted via mTor pathway as supported below. Massive opportunities - PAA could be a game changer!
Slide 13
Souce: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335350/
Source: https://www.mdpi.com/1422-0067/20/3/728
Most excited about the Neurodegenerative preclinical results. Monepantel is a selective mTor inhibitor and reduces autophagy. This is the main driver of Parkinson’s and Alzheimers.
Ann: Singapore Healthcare Day Presentation, page-6
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $77.79M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 34166 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.5¢ | 3417 | 3 |
View Market Depth
| Last trade - 09.30am 09/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |
Day chart unavailable